SEC Form 4 · accession 0001615774-18-010699
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George C Carpenter IV
Officer — Chief Executive Officer
Period of report
Oct 8, 2018
Accepted (ET)
Oct 10, 2018 · 8:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EMPLOYEE STOCK OPTION (right to purchase)F1 | $1.38 | Oct 8, 2018 | A | 48,000 | A | Oct 8, 2018 | Oct 8, 2028 | Common Stock | 48,000 | 48,000 | D |
Explanation of responses
- F1On October 8, 2018, the Reporting Person was granted an option to purchase 48,000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, subject to shareholder approval of an amendment increasing the total shares available for grant thereunder. 6,000 of the options vested on the grant date, with the remainder vesting upon the satisfaction of specified performance targets.